Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis

Multiple Sclerosis

Volumn 9, Issue 1, 2003, Pages 102-107

  Sellebjerg, Finn ^a   Jensen, C V ^a   Larsson, H B W ^a   Frederiksen, J L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acute optic neuritis; Cerebrospinal fluid immunology; Gadolinium enhancement; Immunoglobulins; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

GADOLINIUM; GELATINASE B; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; NEOPTERIN; PLACEBO;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; LEUKOCYTE COUNT; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; VISUAL SYSTEM FUNCTION;

ADULT; ANTI-INFLAMMATORY AGENTS; BLOOD-BRAIN BARRIER; FEMALE; GADOLINIUM; HUMANS; IMMUNOGLOBULIN A; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 0037330434     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458503ms880sr     Document Type: Article

References (32)

1. Andersson P-B, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: A critical review. J Neurol Sci 1998; 160: 16-25.
2. Durelli L, Cocito D, Riccio A, Barile C, Bergamasco B, Baggio GF, Perla F, Delsedime M, Gusmaroli G, Bergamini L. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis. Neurology 1986; 36: 238-43.
3. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-16.
4. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 51: 529-34.
5. Sellebjerg F, Schaldemose Nielsen H, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999; 52: 1479-84.
6. Beck RW, Cleary PA, Anderson MM, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, Savino PJ, Guy JR, Trobe JD, McCrary JA, Smith CH, Chrousos GA, Thompson HS, Katz BJ, Brodsky MC, Goodwin JA, Atwell CW, and the Optic Neuritis Study Group. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326: 581-88.
7. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93.
8. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34: 661-69.
9. Nesbit GM, Forbes GS, Scheihauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: Histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991; 180: 467-74.
10. Burnham JA, Wright RR, Dreisbach J, Murray RS. The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 1991; 41: 1349-54.
11. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991; 41: 1219-22.
12. Miller DH, Thompson AJ, Morrissey SP, MacManus DG, Moore SG, Kendall BE, Moseley IF, McDonald WI. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55: 450-53.
13. Barkhof F, Tas MW, Frequin STFM, Scheltens P, Hommes OR, Nauta JJP, Valk J. Limited duration of the effect of methyl-prednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994; 36: 382-87.
14. Frequin ST, Barkhof F, Lamers KJ, Hommes OR, Borm GF. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methyl-prednisolone. Acta Neurol Scand 1992; 86: 291-97.
15. Barkhof F, Frequin ST, Hommes OR, Lamers K, Scheltens P, Van Geel WJ, Valk J. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992; 42: 63-67.
16. Sellebjerg F, Christiansen M, Jensen J, Frederiksen JL. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol 2000; 7: 281-89.
17. Whitaker JN, Layton BA, Herman PK, Kachelhofer RD, Burgard S, Bartolucci AA. Correlation of myelin basic protein-like material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment. Ann Neurol 1993; 33: 10-17.
18. Frederiksen JL, Larsson HBW, Christiansen P, Sellebjerg FT, Olesen J. Blood-brain barrier impairment in acute optic neuritis evaluated by gadolinium-DTPA enhanced MRI and CSF studies. Eur J Neurol 1996; 3: 560-66.
19. Paty DW, Oger JJ, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, Eisen KA, Purves SJ, Low MD, Brandejs V, Robertson WD, Li DKB. MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38: 180-85.
20. Sellebjerg F, Christiansen M. Qualitative assessment of intrathecal IgG synthesis by isoelectric focusing and immunodetection: Interlaboratory reproducibility and interobserver agreement. Scand J Clin Lab Invest 1996; 56: 135-43.
21. Sellebjerg F, Christiansen M, Rasmussen LS, Jaliachvili I, Nielsen PM, Frederiksen JL. The cerebrospinal fluid in multiple sclerosis. Quantitative assessment of intrathecal immunoglobulin synthesis by empirical formulae. Eur J Neurol 1996; 3: 548-59.
22. Sellebjerg F, Christiansen M, Nielsen PM, Frederiksen JL. Cerebrospinal fluid measures of disease activity in multiple sclerosis. Mult Scler 1998; 4: 475-79.
23. Goodkin DE, Cookfair D, Wende K, Bourdette D, Pullicino P, Scherokman B, Whitman R, and the Multiple Sclerosis Collaborative Research Group. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 1992; 42: 859-63.
24. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC, and the Canadian Cooperative MS Study Group. Interrater variability with the Expanded Disability Status Scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology 1990; 40: 971-75.
25. Thorpe JW, Kidd D, Moseley IF, Kenndall BE, Thompson AJ, MacManus DG, McDonald WI, Miller DH. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996; 46: 373-78.
26. Rovaris M, Mastronardo G, Gasperini C, Prandini F, Yousry TA, Filippi M. MRI evolution of new MS lesions enhancing after different doses of gadolinium. Acta Neurol Scand 1998; 98: 90-93.
27. Filippi M, Rocca MA, Rizzo G, Horsfield MA, Rovaris M, Minicucci L, Colombo B, Comi G. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology 1998; 50: 1289-93.
28. Filippi M, Rocca MA, Comi G. Magnetization transfer ratios of multiple sclerosis lesions with variable durations of enhancement. J Neurol Sci 1998; 159: 162-65.
29. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998; 16: 137-61.
30. Weinberg AD, Whitman R, Swain SL, Morrison WJ, Wyrick G, Hoy C, Vandenbark AA, Offner H. Transforming growth factor-beta enhances the in vivo effector function and memory phenotype of antigen-specific T helper cells in experimental autoimmune encephalomyelitis. J Immunol 1992; 148: 2109-17.
31. Wyss-Coray T, Borrow P, Brooker MJ, Mucke L. Astroglial overproduction of TGF-beta1 enhances inflammatory central nervous system disease in transgenic mice. J Neuroimmunol 1997; 77: 45-50
32. Troiano R, Hafstein M, Ruderman M, Dowling P, Cook S. Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis. Ann Neurol 1984; 15: 257-63.